Your browser doesn't support javascript.
loading
Preparation and characterization of lamotrigine containing nanocapsules for nasal administration.
Gieszinger, Péter; Stefania Csaba, Noemi; Garcia-Fuentes, Marcos; Prasanna, Maruthi; Gáspár, Róbert; Sztojkov-Ivanov, Anita; Ducza, Eszter; Márki, Árpád; Janáky, Tamás; Kecskeméti, Gábor; Katona, Gábor; Szabó-Révész, Piroska; Ambrus, Rita.
Affiliation
  • Gieszinger P; University of Szeged, Inderdisciplinary Excellence Centre, Institute of Pharmaceutical Technology and Regulatory Affairs, Eötvös u. 6., H-6720 Szeged, Hungary.
  • Stefania Csaba N; University of Santiago de Compostela, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), 15782 Campus Vida, Santiago de Compostela, Spain. Electronic address: noemi.csaba@usc.es.
  • Garcia-Fuentes M; University of Santiago de Compostela, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), 15782 Campus Vida, Santiago de Compostela, Spain. Electronic address: marcos.garcia@usc.es.
  • Prasanna M; University of Santiago de Compostela, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), 15782 Campus Vida, Santiago de Compostela, Spain.
  • Gáspár R; Department of Pharmacology and Pharmacotherapy, University of Szeged, Dóm tér 12, H-6720 Szeged, Hungary. Electronic address: gaspar@med.u-szeged.hu.
  • Sztojkov-Ivanov A; Department of Pharmacodynamics and Biopharmacy, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary. Electronic address: Ivanov.Anita@pharm.u-szeged.hu.
  • Ducza E; Department of Pharmacodynamics and Biopharmacy, University of Szeged, Eötvös u. 6, H-6720 Szeged, Hungary. Electronic address: ducza@pharm.u-szeged.hu.
  • Márki Á; Department of Medical Physics and Informatics, University of Szeged, Faculty of Medicine, H-6720 Szeged, Korányi fasor 9., Hungary. Electronic address: marki.arpad@med.u-szeged.hu.
  • Janáky T; Department of Medical Chemistry, University of Szeged, Dóm tér 8, H-6720 Szeged, Hungary. Electronic address: janaky.tamas@med.u-szeged.hu.
  • Kecskeméti G; Department of Medical Chemistry, University of Szeged, Dóm tér 8, H-6720 Szeged, Hungary. Electronic address: kecskemeti.gabor@med.u-szeged.hu.
  • Katona G; University of Szeged, Inderdisciplinary Excellence Centre, Institute of Pharmaceutical Technology and Regulatory Affairs, Eötvös u. 6., H-6720 Szeged, Hungary. Electronic address: katona@pharm.u-szeged.hu.
  • Szabó-Révész P; University of Szeged, Inderdisciplinary Excellence Centre, Institute of Pharmaceutical Technology and Regulatory Affairs, Eötvös u. 6., H-6720 Szeged, Hungary. Electronic address: revesz@pharm.u-szeged.hu.
  • Ambrus R; University of Szeged, Inderdisciplinary Excellence Centre, Institute of Pharmaceutical Technology and Regulatory Affairs, Eötvös u. 6., H-6720 Szeged, Hungary. Electronic address: arita@pharm.u-szeged.hu.
Eur J Pharm Biopharm ; 153: 177-186, 2020 Aug.
Article in En | MEDLINE | ID: mdl-32531424
ABSTRACT
Nanocapsules (NCs) have become one of the most researched nanostructured drug delivery systems due to their advantageous properties and versatility. NCs can enhance the bioavailabiliy of hydrophobic drugs by impoving their solubility and permeability. Also, they can protect these active pharmaceutical agents (APIs) from the physiological environment with preventing e.g. the enzymatic degradation. NCs can be used for many administration routes e.g. oral, dermal, nasal and ocular formulations are exisiting in liquid and solid forms. The nose is one of the most interesting alternative drug administration route, because local, systemic and direct central nervous system (CNS) delivery can be achived; this could be utilized in the therapy of CNS diseases. Therefore, the goal of this study was to design, prepare and investigate a novel, lamotrigin containing NC formulation for nasal administration. The determination of micrometric parameters (particle size, polydispersity index, surface charge), in vitro (drug loading capacity, release and permeability investigations) and in vivo characterization of the formulations were performed in the study. The results indicate that the formulation could be a promising alternative of lamotrigine (LAM) as the NCs were around 305 nm size with high encapsulation efficiency (58.44%). Moreover, the LAM showed rapid and high release from the NCs in vitro and considerable penetration to the brain tissues was observed during the in vivo study.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Nanocapsules / Lamotrigine Limits: Animals Language: En Journal: Eur J Pharm Biopharm Journal subject: FARMACIA / FARMACOLOGIA Year: 2020 Type: Article Affiliation country: Hungary

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Nanocapsules / Lamotrigine Limits: Animals Language: En Journal: Eur J Pharm Biopharm Journal subject: FARMACIA / FARMACOLOGIA Year: 2020 Type: Article Affiliation country: Hungary